The WHOQOL-BREF: a modern psychometric evaluation of its internal construct validity in people with multiple sclerosis

被引:0
作者
I. M. Pomeroy
A. Tennant
R. J. Mills
C. A. Young
机构
[1] Walton Centre NHS Foundation Trust,Department of Neurology
[2] University of Leeds,Leeds Institute of Rheumatic and Musculoskeletal Medicine
[3] University of Liverpool,undefined
来源
Quality of Life Research | 2020年 / 29卷
关键词
Multiple sclerosis; Rasch analysis; Clinical outcomes; Quality of life;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:1961 / 1972
页数:11
相关论文
共 169 条
  • [1] Ploughman M(2014)The Canadian survey of health, lifestyle and ageing with multiple sclerosis: Methodology and initial results British Medical Journal Open 4 e0057118-126
  • [2] Beaulieu S(2015)Multiple sclerosis: Etiology, symptoms, incidence and prevalence, and implications for community living and employment Work 265 119-2166
  • [3] Harris C(2018)Changes in disability in people with multiple sclerosis: A 10-year prospective study Journal of Neurology 98 2160-65
  • [4] Hogan S(2017)How do pain, fatigue, depressive, and cognitive symptoms relate to well-being and social and physical functioning in the daily lives of individuals with multiple sclerosis? Archives of Physical Medicine and Rehabilitation 273 59-185
  • [5] Manning OJ(2018)Quality of life and psychological well-being in the early stages of multiple sclerosis (MS): Importance of adopting a biopsychosocial model Disability and Health Journal 8 179-426
  • [6] Alderdice PW(1995)Linking clinical variables with health-related quality of life: A conceptual model of patient outcomes JAMA: The Journal of the American Medical Association 362 416-1828
  • [7] Godwin M(2018)Identifying priority outcomes that influence selection of disease-modifying therapies in MS Neurology: Clinical Practice 380 1819-1428
  • [8] Bishop M(2010)A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis New England Journal of Medicine 36 1958-234
  • [9] Rumrill PD(2012)Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: A randomised controlled phase 3 trial The Lancet 373 1418-627
  • [10] Conradsson D(2014)Effects of delayed-release dimethyl fumarate (DMF) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: An integrated analysis of the phase 3 DEFINE and CONFIRM studies Clinical Therapeutics 376 221-1488